AVT-12 Weight Loss Drug Product Study Concludes
The weight loss combination drug product, AVT-12 has most recently been the subject of a year-long phase III randomized, double-blind, placebo-controlled efficacy trial, conducted by ITCES Corporation.
Los Angeles, CA, March 05, 2010 --(PR.com)-- Discovered by Stanford University School of Medicine in 2005, obestatin has repeatedly demonstrated an ability to positively modify certain natural overfeeding behaviors which contribute to obesity.
AVT-12 is thought to improve GPR39 G protein-coupled receptor affinity to obestatin Zn(2+) and associated peptides shown effective in weight loss. Importantly, the natural serum levels of obestatin are not altered.
Through improving GPR39 receptor affinity, rather than increasing total levels of obestatin, negative feedback compensation is reduced, contributing to marked improvements in long-term outcome. In brief:
Over the course of the year-long study, the AVT-12 Treatment Group lost an average of 39.3% of their baseline bodyweight vs. 3.4% for the placebo control group.
Even more impressive, were the improvements noted in blood profiles, including C-Reactive Protein (CRP), a risk factor for cardiovascular disease.
About ITCES:
ITCES Corporation partners with innovators to evaluate and develop applied biotherapeutics from concept to market. ITCES delivers timely value to clients by facilitating and analyzing critical research, while protecting intellectual property.
###
AVT-12 is thought to improve GPR39 G protein-coupled receptor affinity to obestatin Zn(2+) and associated peptides shown effective in weight loss. Importantly, the natural serum levels of obestatin are not altered.
Through improving GPR39 receptor affinity, rather than increasing total levels of obestatin, negative feedback compensation is reduced, contributing to marked improvements in long-term outcome. In brief:
Over the course of the year-long study, the AVT-12 Treatment Group lost an average of 39.3% of their baseline bodyweight vs. 3.4% for the placebo control group.
Even more impressive, were the improvements noted in blood profiles, including C-Reactive Protein (CRP), a risk factor for cardiovascular disease.
About ITCES:
ITCES Corporation partners with innovators to evaluate and develop applied biotherapeutics from concept to market. ITCES delivers timely value to clients by facilitating and analyzing critical research, while protecting intellectual property.
###
Contact
ITCES Corporation
Paul Roth
2132836570
ITCES-Corp.com
Paul Roth
2132836570
ITCES-Corp.com
Contact
Categories